Patents Issued in October 1, 2020
  • METHODS OF TREATING BONE LOSS
    Publication number: 20200306232
    Abstract: Provided are compositions and methods for preventing, mitigating, decreasing, inhibiting and/or reversing bone loss and/or increasing and/or promoting bone regeneration and remodeling and/or preventing, mitigating, decreasing, inhibiting and/or reversing periodontitis and/or periodontal disease in a subject by administering to the subject an effective amount of an inhibitor of soluble epoxide hydrolase (sEH).
    Type: Application
    Filed: June 8, 2017
    Publication date: October 1, 2020
    Inventors: Carlos Antonio TRINDADE DA SILVA, Buce D. HAMMOCK, Fawaz G. HAJ, Ahmed BETTAIEB, Ahmet Bora INCEOGLU
  • Cytotoxic Actin-Targeting Compounds
    Publication number: 20200306233
    Abstract: A class of compounds useful in pharmaceutical compositions and methods for treating or preventing cancer is described. Analogs of Mycalolide B have been prepared and tested in breast and ovarian cancer cell lines. The compounds show utility for inhibition of survival and proliferation of tumor cells. The compounds have been shown to disrupt actin.
    Type: Application
    Filed: August 17, 2018
    Publication date: October 1, 2020
    Inventors: Rebecca Grange, John Allingham, Andrew Craig, P. Andrew Evans, Madhu Aeluri
  • RADIATION MITIGATOR AND METHOD OF USE THEREOF
    Publication number: 20200306234
    Abstract: Provided are methods useful for preventing and mitigating radiation injury, including acute radiation syndrome, comprising administering to a subject a therapeutically effective amount of a compound represented by formula I: or a pharmaceutically acceptable salt thereof, wherein Z is —O—or —N(H)—.
    Type: Application
    Filed: March 31, 2017
    Publication date: October 1, 2020
    Inventors: Milton L. Brown, Yali Kong, Courtney Houchen, Sripathi M. Sureban, Parthasarathy Chandrakesan
  • COMPOSITIONS AND METHODS FOR TREATING RHEUMATOID ARTHRITIS
    Publication number: 20200306235
    Abstract: Disclosed are methods and compositions for treating ore preventing a STAT5-mediated medical condition, e.g., rheumatoid arthritis, in a subject by administering to the subject a therapeutically effective amount of a compound, the compound being a STAT5 inhibitor, or a pharmaceutically acceptable salt of the STAT5 inhibitor, or a solvate of the STAT5 inhibitor, or a prodrug of the STAT5 inhibitor. In one example, the compound used in the methods and compositions is pimozide. In another example, the compound used in the methods and compositions is nicotinohydrazide.
    Type: Application
    Filed: May 4, 2018
    Publication date: October 1, 2020
    Applicant: Generos Biopharma Ltd.
    Inventor: Xin-Yuan Fu
  • COMBINATION THERAPIES AND USES THEREOF
    Publication number: 20200306236
    Abstract: The present disclosure relates to combination therapies containing one or more PARP inhibitors and one or more angiogenesis inhibitor. Also described herein are therapeutic uses of such combination therapies for treating various disorders and conditions. The combination therapies and uses thereof can be useful for preventing tumor cell growth, preventing tumor metastasis, inducing an immune response or enhancing an immune response.
    Type: Application
    Filed: October 5, 2018
    Publication date: October 1, 2020
    Inventors: Keith W. Mikule, Zebin Wang, Yinghui Zhou
  • METHODS OF DIAGNOSING AND TREATING TOURETTE SYNDROME
    Publication number: 20200306237
    Abstract: Methods and uses for diagnosing and treating Tourette syndrome are encompassed, wherein diagnosis and treatment may be based upon an assessment of genetic alterations in metabotropic glutamate receptor (mGluR) network genes and wherein treatment is with nonspecific activators of mGluRs such as fasoracetam.
    Type: Application
    Filed: March 4, 2020
    Publication date: October 1, 2020
    Inventors: Hakon Hakonarson, Charlly Kao
  • TREATMENT OF CNS CONDITIONS
    Publication number: 20200306238
    Abstract: Aspects of the present invention relate to a method of treating an epileptic encephalopathy in a mammal in need thereof, comprising administering a composition comprising an effective amount of (4-benzyl-4-hydroxypiperidin-1-yl) (2,4?-bipyridin-3-yl)methanone or a pharmaceutically acceptable salt thereof to the mammal.
    Type: Application
    Filed: August 30, 2018
    Publication date: October 1, 2020
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Toshiya NISHI, Shinichi KONDO
  • OPHTHALMIC COMPOSITION
    Publication number: 20200306239
    Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.
    Type: Application
    Filed: February 7, 2020
    Publication date: October 1, 2020
    Inventors: Gregory I. OSTROW, Kenneth J. WIDDER, David S. BAKER, Harun TAKRURI
  • COMPOSITIONS AND METHODS FOR TREATMENT OF SYMPTOMS IN PARKINSON'S DISEASE PATIENTS
    Publication number: 20200306240
    Abstract: The invention provides dosage forms and methods utilizing nicotine to treat symptoms of a neurologic disorder. In some embodiments, the invention provides compositions for treatment of gait and balance problems associated with Parkinson's Disease.
    Type: Application
    Filed: April 13, 2020
    Publication date: October 1, 2020
    Inventor: Arasteh Ari AZHIR
  • MARKERS OF TISSUE AGING AND USES THEREFOR
    Publication number: 20200306241
    Abstract: Provided herein are methods of detecting or determining aging and/or oxidative damage in tissue, including placental tissue, skin, kidney and brain tissue. One embodiment provides a method for detecting or determining aging in body tissue, comprising measuring one or more markers of aldehyde oxidase 1 (AOX1) expression or activity in a biological sample, wherein the level of AOX1 expression or activity, or of the one or more markers, is indicative of aging in the tissue. Also provided herein are methods of treating a disease or condition associated with ageing or oxidative damage in one or more cells or tissues, comprising administering to a subject in need thereof an inhibitor of AOX1.
    Type: Application
    Filed: March 2, 2018
    Publication date: October 1, 2020
    Inventors: Roger Smith, Kaushik Maiti
  • NOVEL PROCESS FOR THE PREPARATION OF LIFITEGRAST
    Publication number: 20200306242
    Abstract: The present invention relates to a novel process for the preparation of lifitegrast of Formula I. The present invention further provides a novel process for the purification of lifitegrast of Formula I.
    Type: Application
    Filed: September 20, 2018
    Publication date: October 1, 2020
    Inventors: Jigar Tarun Kumar BHAVSAR, Rakesh TIWARI, Bhuwan BHASHKAR, Anil KUMAR
  • COMPOUNDS AND CONJUGATES THEREOF
    Publication number: 20200306243
    Abstract: A conjugate comprising the following topoisomerase inhibitor derivative (A*): with a linker for connecting to a Ligand Unit, wherein the linker is attached in a cleavable manner to the amino residue. The Ligand Unit is preferably an antibody. Also provided is A* with the linking unit attached, and intermediates for their synthesis, as well as the released warhead.
    Type: Application
    Filed: March 23, 2020
    Publication date: October 1, 2020
    Inventors: Philip Wilson Howard, Niall Dickinson, Thais Cailleau, Luke Masterson, William Goundry
  • WNT INHIBITORS FOR USE IN THE TREATMENT OF FIBROSIS
    Publication number: 20200306244
    Abstract: The present disclosure relates to a Wingless-type (wnt) inhibitor of formula (I) for use in the treatment of fibrosis and some fibrosis mediated disorders such as stiff skin syndrome and systemic sclerosis. The present disclosure also provides a method for the treatment of fibrosis, a pharmaceutical combination comprising a wnt inhibitor of formula (I) and a second active ingredient for use in the treatment of fibrosis and also the use of a wnt inhibitor of formula (I) or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of fibrosis and fibrosis mediated disorders.
    Type: Application
    Filed: June 20, 2017
    Publication date: October 1, 2020
    Applicant: Novartis AG
    Inventors: Jennifer Leslie HARRIS, Peter GERGELY, Jun LIU, Eric SVENSSON
  • N-FORMYL VORTIOXETINE AND PREPARATION METHOD THEREOF AND SOLID PREPARATION OF VORTIOXETINE
    Publication number: 20200306245
    Abstract: Disclosed is N-formyl vortioxetine, and also disclosed is a method for preparing the N-formyl vortioxetine and a stable solid preparation of vortioxetine.
    Type: Application
    Filed: September 20, 2017
    Publication date: October 1, 2020
    Inventors: Jinsheng LIN, Tianpei HUANG, Feifei LAN, Xiaoyan XU, Libin HU, Dan LI, Wenquan ZHU, Min LI, Zhiyun WANG
  • LOW-DOSE TRIPLE COMBINATION FORMULATION
    Publication number: 20200306246
    Abstract: Provided herein are pharmaceutical compositions that are useful for the treatment of diabetes and associated conditions, diseases, and disorders.
    Type: Application
    Filed: March 25, 2019
    Publication date: October 1, 2020
    Inventors: Stephen MacMAHON, Anthony RODGERS
  • NOVEL METHODS
    Publication number: 20200306247
    Abstract: The present disclosure relates to pharmaceutical capsules comprising lumateperone, in free, or pharmaceutically acceptable salt form, optionally in combination with one or more additional therapeutic agents, processes for manufacture thereof and methods of use in the treatment or prophylaxis of disease.
    Type: Application
    Filed: June 16, 2020
    Publication date: October 1, 2020
    Applicant: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Peng LI, Robert DAVIS
  • FORMULATIONS FOR SUBSTITUTED 3-PYRROLIDINES, COMPOSITIONS CONTAINING, AND USES OF, SAME
    Publication number: 20200306248
    Abstract: Pharmaceutical carriers which provide an environment of physical and chemical stability comprising a therapeutically effective amount of an active pharmaceutical ingredient (API) compound of structure I, one or more antioxidants, one or more chelators and a vehicle base comprising water and one or more pharmaceutically acceptable non-aqueous solvents, one or more absorption enhancers, one or more gelling agents and one or more pH buffering agents are described.
    Type: Application
    Filed: June 6, 2017
    Publication date: October 1, 2020
    Applicant: GDD Therapeutics, LLC
    Inventors: Nigel R.A. Beeley, J. Gordon Foulkes, Kieran George Mooney, Charles Rodney Greenaway Evans, Keith Arthur Johnson, Howard G. Welgus, Celia P. Jenkinson, James R. Hauske
  • MEDICAMENT
    Publication number: 20200306249
    Abstract: An object of the present invention is to provide a medicament for preventing or treating pulmonary hypertension. The present invention provides a medicament for preventing or treating pulmonary hypertension, comprising a compound selected from the group consisting of (5R)-N-[1-ethyl-1-(4-ethylphenyl)propyl]-2,7,7-trimethyl-5-phenyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, (5R)-N-[1-ethyl-1-(4-methoxyphenyl)propyl]-2,7,7-trimethyl-5-phenyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, (5R)-N-[1-ethyl-1-(4-ethylphenyl)propyl]-5-(2-fluorophenyl)-2,7,7-trimethyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, and the salt thereof.
    Type: Application
    Filed: March 27, 2017
    Publication date: October 1, 2020
    Inventors: Juran KATO, Hiroko YAMAKAWA, You MURAKI, Gattu MAHANANDEESHWAR, Oruganty SATYALAKSHMI
  • Combination Treatment for Neuropsychiatric Disorders
    Publication number: 20200306250
    Abstract: Given its various activities in the brain, nitric oxide (NO) has been associated with various neuropsychiatric diseases and/or neuropsychiatric disorders, including schizophrenia. In fact, evidence has been accumulating to show that abnormalities in NO levels are associated with schizophrenia. Among a number of NO's neural mechanisms associated with schizophrenia, its role as a second messenger of NMDA reccptor activation, which interacts with both dopaminergic and serotonergic pathways, has been of particular focus. It demonstrated herein that a combined administration of nitric oxide synthase substrates and co-factors display antineuropsychiatric activity and cognitive benefit by re-establishing homeostatic nitric oxide production.
    Type: Application
    Filed: September 27, 2018
    Publication date: October 1, 2020
    Inventor: Xiaoduo Fan
  • SOLID DISPERSION
    Publication number: 20200306251
    Abstract: The present invention relates to a solid dispersion containing a compound represented by General Formula (1): wherein R1 is an unsubstituted phenyl group or a phenyl group substituted with a substituent; the substituent is an alkyl group having 1 to 8 carbon atoms, an alkyl group having 1 to 8 carbon atoms substituted with a halogen atom, an alkoxy group having 1 to 8 carbon atoms, an alkoxycarbonyl group having 2 to 8 carbon atoms, a formyl group, a carboxyl group, a halogen atom, a phenyl group or a phenoxy group; R2 is a cyano group or a nitro group; R3 is a hydroxyl group; X is an oxygen atom or —S(O)n—; n is an integer of 0 to 2; Y is an oxygen atom or a sulfur atom, or a pharmaceutically acceptable salt thereof and a hypromellose derivative.
    Type: Application
    Filed: November 28, 2018
    Publication date: October 1, 2020
    Inventors: Shigeru Itai, Shuji Noguchi, Yasunori Iwao, Masuharu Hirano, Takashi Ohta, Tomio Yamakawa
  • COMPOSITION FOR PREVENTING AND/OR TREATING DEMENTIA
    Publication number: 20200306252
    Abstract: A composition, comprising a first component and a second component, wherein the first component is at least one of xanthine and a derivative of xanthine, and the second component is at least one of diarylheptanoid, a derivative of diarylheptanoid, catechin, an ester of catechin, flavonoid, and isoflavonoid, and wherein the first component is optionally combined with the second component as an adduct. The composition could be used to treat and/or prevent dementia.
    Type: Application
    Filed: July 12, 2019
    Publication date: October 1, 2020
    Inventor: Eric Yueh-Lang SHEU
  • Therapeutic Modulators of the Reverse Mode of ATP Synthase
    Publication number: 20200306253
    Abstract: Compounds of the following formula (I) slow the ATP-hydrolysing mode of ATP synthase and are useful for treating various diseases and disorders including cancer, particularly cancers that utilise the Warburg effect.
    Type: Application
    Filed: July 13, 2018
    Publication date: October 1, 2020
    Inventor: Michael David Forrest
  • COMBINATION OF ERK1/2 INHIBITOR COMPOUND WITH GEMCITABINE OR WITH GEMCITABINE AND NAB-PACLITAXEL FOR USE IN TREATMENT OF PANCREATIC CANCER
    Publication number: 20200306254
    Abstract: The present invention provides a combination of an ERK1/2 inhibitor compound, 6,6-dimethyl-2-{2-[(1-methyl-1H-pyrazol-5-yl)amino]pyrimidin-4-yl}-5-[2-(morpholin-4-yl) ethyl]-5,6-dihydro-4H-thieno[2,3-c]pyrrol-4-one, or a pharmaceutically acceptable salt thereof with gemcitabine, or a pharmaceutically acceptable salt thereof preferably hydrochloride, or with gemcitabine, or a pharmaceutically acceptable salt thereof preferably hydrochloride, and nab-paclitaxel, and to methods of using the combination to treat certain disorders, such as pancreatic cancer, including pancreatic ductal adenocarcinoma (PDAC).
    Type: Application
    Filed: June 22, 2017
    Publication date: October 1, 2020
    Inventors: Shripad BHAGWAT, Ramon Velasquez TIU, Wenjuan WU
  • COMPOSITIONS AND METHODS FOR TREATING NIEMANN PICK C DISEASE
    Publication number: 20200306255
    Abstract: The present invention relates to the use of PIKfyve inhibitors to treat Niemann-Pick disease type C, and related compositions and methods.
    Type: Application
    Filed: February 5, 2020
    Publication date: October 1, 2020
    Inventors: Chris Conrad, Jonathan M. Rothberg, Tian Xu, Henri Lichenstein
  • BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS
    Publication number: 20200306256
    Abstract: The present disclosure relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR3 and/or FGFR4 enzyme and are useful in the treatment of FGFR-associated diseases.
    Type: Application
    Filed: March 12, 2020
    Publication date: October 1, 2020
    Inventors: Liang Lu, Bo Shen, Alexander Sokolsky, Xiaozhao Wang, Liangxing Wu, Wenqing Yao, Yingda Ye
  • KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE
    Publication number: 20200306257
    Abstract: The present invention is directed to kinase inhibitor compounds having the following structure: or a stereoisomer, pharmaceutically acceptable salt, oxide, or solvate thereof, where R1, R2, X, n, R3, Y, Z, R4, R5, R6, and = are as defined herein. The present invention also relates to compositions containing the kinase inhibitor compounds, methods of inhibiting activity of a kinase in a cell, methods of increasing cell proliferation in a population of pancreatic beta cells, methods of treating a subject for a condition associated with insufficient insulin secretion, and methods of treating a subject for a neurological disorder.
    Type: Application
    Filed: November 20, 2018
    Publication date: October 1, 2020
    Inventors: Robert DEVITA, Andrew STEWART, Avner SCHLESSINGER, Kunal KUMAR, Peter MAN-UN UNG, Hui WANG, Hailing LI
  • TARGETING THE TLK1/NEK1 AXIS IN PROSTATE CANCER
    Publication number: 20200306258
    Abstract: A method of treating prostate cancer in a patient comprising administering to the patient a pharmaceutical composition including a first therapeutic including a TLK1B inhibitor, or a pharmaceutically acceptable salt, solvate, ester, amide, clathrate, stereoisomer, enantiomer, prodrug or analog thereof, and a second therapeutic including an antiandrogen or a pharmaceutically acceptable salt, solvate, ester, amide, clathrate, stereoisomer, enantiomer, prodrug or analog thereof.
    Type: Application
    Filed: March 30, 2020
    Publication date: October 1, 2020
    Inventors: Arrigo DeBENEDETTI, Siddhant BHOIR, Vibha SINGH, Javeena HUSSAIN, Rupesh CHIKHALE, Richard BRYCE, Sivapriya KIRUBAKARAN
  • SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY
    Publication number: 20200306259
    Abstract: Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Application
    Filed: April 8, 2020
    Publication date: October 1, 2020
    Inventors: Xiangping QIAN, Yong-Liang ZHU
  • COMPOSITIONS OF MIDAZOLAM FOR BUCCAL ADMINISTRATION IN THE TREATMENT OF SEIZURES TO OBTAIN RAPID ONSET OF ACTION
    Publication number: 20200306260
    Abstract: The present invention relates to a unit dosage composition in the form of a film or a water containing from 0.25 mg to 2 mg of midazolam or a pharmaceutically acceptable salt thereof, and a film-forming substance.
    Type: Application
    Filed: March 6, 2020
    Publication date: October 1, 2020
    Applicant: SWIPP AB
    Inventor: Christer SJÖGREN
  • COMPOUNDS, COMPOSITIONS AND METHODS FOR PREVENTION AND/OR TREATMENT OF CANCER
    Publication number: 20200306261
    Abstract: The present invention includes compounds, compositions and methods that are useful for preventing or treating melanoma or any other cancer in a subject, such as a GPCR-expressing cancer. In certain embodiments, the compounds comprise estrogen (including estrogen derivatives or analogues), a selective GPER agonist and/or another G-protein coupled receptor (GPCR) agonist that increases cancer cell differentiation.
    Type: Application
    Filed: May 31, 2017
    Publication date: October 1, 2020
    Inventors: Todd RIDKY, Christopher NATALE, Jeffrey WINKLER
  • COMPOUNDS AND METHODS OF THEIR USE
    Publication number: 20200306262
    Abstract: Compounds, compositions, and methods for treating injuries caused by exposure to chemical warfare and similar agents are described herein.
    Type: Application
    Filed: November 18, 2016
    Publication date: October 1, 2020
    Inventor: James J. Doherty
  • TOPICAL FORMULATION FOR INFLAMMATORY SKIN CONDITIONS
    Publication number: 20200306263
    Abstract: The present disclosure provides a formulation for inflammatory skin conditions comprising about 0.05% to 10% by weight of colloidal oatmeal, about 5% about 30% by weight of coconut oil, about 0.25% to about 5% by weight of a corticosteroid, and a pharmaceutically acceptable carrier, emollient and/or diluent. The formulation further comprises in certain embodiments ferulic acid, petrolatum, a wax, and/or a silicone. The present disclosure further provides methods of treating, preventing or reducing the symptoms of inflammatory skin conditions, including eczema, psoriasis and seborrheic dermatitis, comprising topically administering to an affected area of skin a therapeutically effective amount of the formulations disclosed herein.
    Type: Application
    Filed: March 27, 2019
    Publication date: October 1, 2020
    Inventors: Peter Lio, Kevin Fowler, Michael Pietrangelo
  • AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUND AND USES THEREOF
    Publication number: 20200306264
    Abstract: Disclosed herein are formulations of pirfenidone or pyridone analog compounds for aerosolization and use of such formulations for aerosol administration of pirfenidone or pyridone analog compounds for the prevention or treatment of various fibrotic and inflammatory diseases, including disease associated with the lung, heart, kidney, liver, eye and central nervous system. In some embodiments, pirfenidone or pyridone analog compound formulations and delivery options described herein allow for efficacious local delivery of pirfenidone or pyridone analog compound. Compositions include all formulations, kits, and device combinations described herein. Methods include inhalation procedures, indications and manufacturing processes for production and use of the compositions described.
    Type: Application
    Filed: April 3, 2020
    Publication date: October 1, 2020
    Applicant: Avalyn Pharma Inc.
    Inventor: Mark William Surber
  • NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF
    Publication number: 20200306265
    Abstract: Described herein are methods of treating a disorder, e.g., tremor, e.g., essential tremor; depression, e.g., postpartum depression; and anxiety disorder, the method comprising administering to a human subject suffering from a disorder, e.g., tremor, e.g., essential tremor, depression, e.g., postpartum depression, an anxiety disorder with a neuroactive steroid or a composition comprising a neuroactive steroid (e.g., pregnanolone, allopregnanolone, alphadalone, ganaxolone, or alphaxolone).
    Type: Application
    Filed: March 8, 2017
    Publication date: October 1, 2020
    Inventors: Stephen Jay Kanes, Helen Colquhoun
  • SOLID DISPERSION OF DUTASTERIDE, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
    Publication number: 20200306266
    Abstract: A solid dispersion of dutasteride for improving the solubility or dissolution rate of poorly soluble dutasteride, a method for preparing the solid dispersion, and a pharmaceutical composition including the solid dispersion are provided. The solid dispersion includes: a coprecipitate including dutasteride and a water-soluble polymeric carrier; and an adsorbent. The dutasteride and the water-soluble polymeric carrier are present in a weight ratio of 1:10-100 in the coprecipitate. The solid dispersion exhibits a dissolution rate equal to or higher than AVODART® soft capsules and contains a minimal amount of related substances, achieving good storage stability.
    Type: Application
    Filed: November 12, 2018
    Publication date: October 1, 2020
    Inventors: Dae Ik KIM, Woo Cheoul SHIN
  • Nutritional Intervention for Improving Muscular Function and Strength
    Publication number: 20200306267
    Abstract: The present invention provides a composition comprising HMB and Vitamin D. Methods of administering HMB and Vitamin D to an animal are also described. Vitamin D and HMB are administered to increase muscle mass, strength, and functionality. The combination of Vitamin D and HMB together has a synergistic effect, which results in a surprising and unexpected level of improvement in muscle mass, strength and functionality.
    Type: Application
    Filed: June 17, 2020
    Publication date: October 1, 2020
    Inventors: John Rathmacher, John Fuller, JR., Shawn Baier, Steve Nissen, Naji Abumrad
  • VITAMIN COMPOSITION
    Publication number: 20200306268
    Abstract: A composition including nanoparticles encapsulating a vitamin, wherein the vitamin is surrounded by lipids for delivery through mucous membranes. A composition including nanoparticles encapsulating a vitamin, the nanoparticles including medium chain triglycerides, lecithin, cholesterol, and polysorbate 80. A pharmaceutical composition, including nanoparticles encapsulating a vitamin, the nanoparticles including medium chain triglycerides, lecithin, cholesterol, and polysorbate 80 in a pharmaceutically acceptable carrier. A method of making the composition, by forming nanoparticles encapsulating a vitamin, wherein the vitamin is surrounded by lipids for delivery through mucous membranes.
    Type: Application
    Filed: March 18, 2020
    Publication date: October 1, 2020
    Applicant: Tempus Bio Technologies LLC
    Inventor: Tracy L. Holdford
  • ANTIBACTERIAL USE OF HALOGENATED SALICYLANILIDES
    Publication number: 20200306269
    Abstract: The invention relates to a halogenated salicylanilide selected from closantel, rafoxanide, oxyclozanide and niclosam-ide and derivatives thereof including salts, hydrates, esters and the like for use in the topical treatment or prevention of infections caused by Gram-positive bacteria such as Staphylococcus, in particular Staphylococcus aureus, and Streptococcus, in particular Streptococcus pyogenesGrain positive bacteria treated with the halogenated salicylanilides exhibit a very low frequency of appear-ance of resistant mutants compared to commonly used topical antibiotics.
    Type: Application
    Filed: June 12, 2020
    Publication date: October 1, 2020
    Inventors: Emilie Flora Aurore DELAVENNE, Daniel Jean Jacques SIMON, Morten Otto Alexander SOMMER, Rasmus Vendler TOFT-KEHLER
  • ANTIBACTERIAL USE OF HALOGENATED SALICYLANILIDES
    Publication number: 20200306270
    Abstract: The invention relates to a halogenated salicylanilide selected from closantel, rafoxanide, oxyclozanide and niclosamide and derivatives thereof including salts, hydrates, esters and the like for use in the topical treatment or prevention of infections caused by Gram-positive bacteria such as Staphylococcus, in particular Staphylococcus aureus, and Streptococcus, in particular Streptococcus pyogenes. Grain positive bacteria treated with the halogenated salicylanilides exhibit a very low frequency of appearance of resistant mutants compared to commonly used topical antibiotics.
    Type: Application
    Filed: June 12, 2020
    Publication date: October 1, 2020
    Inventors: Emilie Flora Aurore DELAVENNE, Daniel Jean Jacques SIMON, Morten Otto Alexander SOMMER, Rasmus Vendler TOFT-KEHLER
  • ANTIBACTERIAL USE OF HALOGENATED SALICYLANILIDES
    Publication number: 20200306271
    Abstract: The invention relates to a halogenated salicylanilide selected from closantel, rafoxanide, oxyclozanide and niclosamide and derivatives thereof including salts, hydrates, esters and the like for use in the topical treatment or prevention of infections caused by Gram-positive bacteria such as Staphylococcus, in particular Staphylococcus aureus, and Streptococcus, in particular Streptococcus pyogenes. Grain positive bacteria treated with the halogenated salicylanilides exhibit a very low frequency of appearance of resistant mutants compared to commonly used topical antibiotics.
    Type: Application
    Filed: June 12, 2020
    Publication date: October 1, 2020
    Inventors: Emilie Flora Aurore DELAVENNE, Daniel Jean Jacques SIMON, Morten Otto Alexander SOMMER, Rasmus Vendler TOFT-KEHLER
  • Lipid Disulfide Prodrugs and Uses Related Thereto
    Publication number: 20200306272
    Abstract: This disclosure relates to lipid disulfide prodrugs and in particular to lipid disulfide phosphodiester nucleosides and derivatives thereof, pharmaceutical compositions, and uses related thereto. According to one embodiment of the disclosure there is provided a compound of Formula I, or pharmaceutically acceptable salts or derivatives thereof, wherein substituents are disclosed herein.
    Type: Application
    Filed: June 12, 2020
    Publication date: October 1, 2020
    Inventors: Dennis Liotta, Kyle Giesler
  • ALK PROTEIN DEGRADATION AGENT AND ANTI-TUMOR APPLICATION THEREOF
    Publication number: 20200306273
    Abstract: A compound of formula (I) and its antitumor application are disclosed. The compounds of formula (I) have degradation and inhibitory effects on ALK target proteins. They are mainly composed of four parts: the first part, ALK-TKI, being compounds with ALK tyrosine kinase inhibitory activity; the second part, LIN, being different kinds of linker (Linker); the third part, the ULM, being a small molecule ligand (ULM, ubiquitin ligase binding moiety) with ubiquitination of VHL, CRBN or other proteases; and the fourth part, the group A, being a carbonyl group or absent, which covalently bond ALK-TKI to LIN, wherein LIN and ULM are covalently bonded. A series of compounds designed and synthesized by the present disclosure have wide pharmacological activities, have functions of degrading ALK protein and inhibiting ALK activity, and can be used for related tumor treatment.
    Type: Application
    Filed: June 15, 2020
    Publication date: October 1, 2020
    Applicant: ShanghaiTech University
    Inventors: Xiaobao Yang, Biao Jiang, Xiaoling Song, Haifan Lin, Ning Sun, Jinju Chen, Xing Qiu, Chaowei Ren, Ying Kong
  • NOVEL THERAPIES FOR TREATING AND PREVENTING CHRONIC RHINOSINUSITIS
    Publication number: 20200306274
    Abstract: The invention provides compositions and methods for disrupting preformed bacterial biofilm or preventing formation of bacterial biofilm. Also provided in the invention are methods and compositions for treating and preventing chronic rhinosinusitis. Such compositions and methods utilize one or more antibiotic compounds in combination with at least one phospholipid compound described herein.
    Type: Application
    Filed: September 21, 2018
    Publication date: October 1, 2020
    Inventors: Charles G. COCHRANE, Ronald A. SIMON, Stephen W. BURGESS, Walter A. SHAW
  • aPKC INHIBITORS AND METHODS OF TREATING A NEURODEGENERATIVE DISEASE OR DISORDER
    Publication number: 20200306275
    Abstract: Provided herein are formulations effective for and methods of treating or preventing a neurodegenerative disorder in a subject in need thereof that can include administering an amount of an aPKC inhibitor to a subject in need thereof.
    Type: Application
    Filed: March 25, 2017
    Publication date: October 1, 2020
    Applicant: University of South Florida
    Inventors: ROBERT VITO FARESE, MINI PALIYATH SAJAN, MARGARET GENEVIEVE HIGGS
  • Methods and Compositions for Prevention and Treatment of Apicomplexan Infections
    Publication number: 20200306276
    Abstract: Methods and compositions for preventing and/or treating diseases and conditions caused by certain apicomplexan infections are provided. The methods involve administering/providing to a subject one or more of tartrolon D and E, including isomers thereof. Exemplary apicomplexan infections that are prevented/treated by the compounds of the invention include those caused by Cryptosporidium, Babesia, Cyclospora, Isospora, Plasmodium, Sarcocystis, Besnoitia, Hammondia, Neospora, Theileria and Toxoplasma.
    Type: Application
    Filed: December 7, 2017
    Publication date: October 1, 2020
    Inventors: Roberta O'CONNOR, Eric W. SCHMIDT
  • DAIRY PRODUCT AND PROCESS
    Publication number: 20200306277
    Abstract: A method of producing sialyloligosaccharides a sialyloligosaccharides-containing source that also contains carbohydrates and minerals. The process includes subjecting the source to a temperature of from about 67° C. and (i) filtration with a heat-resistant filter at a temperature of about 35 to about 95° C. to produce a first retentate and first permeate, or (ii) centrifugal separation to produce a light phase and a heavy phase and filtration of the light phase at a temperature of about 50 to about 70° C. to produce a first retentate and first permeate, (b) nanofiltration of the first permeate, or nanofiltration and diafiltration of the first permeate, to produce a second retentate and second permeate, and (c) concentration of the second retentate, to produce a sialyloligosaccharide-containing extract.
    Type: Application
    Filed: June 9, 2020
    Publication date: October 1, 2020
    Inventors: Alan David WELMAN, Geoffrey STEVENS, Christopher Paul MCJARROW, Bertram Yin FONG, Bing WANG
  • COMPOSITION CONTAINING ARALOSIDE FOR EXTERNAL APPLICATION TO SKIN
    Publication number: 20200306278
    Abstract: The present invention relates to a composition comprising an araloside-based compound and, more particularly, to a composition for external application to skin, the composition comprising, as an active component, an araloside-based compound, including araloside X, araloside V and araloside VII. Thus, the composition restores skin markers damaged by external environmental stress, such as harmful substances or fine dusts, and reduces the expression of skin inflammatory factors to help the recovery of damaged skin, thereby providing effects, such as anti-oxidation, skin trouble suppression, anti-inflammation, or skin barrier improvement.
    Type: Application
    Filed: November 30, 2016
    Publication date: October 1, 2020
    Applicant: Amorepacific Corporation
    Inventors: Jin Sup SHIM, Jae Young KO, Mi Suk YANG, Se Jin YOO, Ho Hyun SONG, Yong Jin KIM, Jon Hwan LEE
  • METHOD FOR SYNTHETICALLY PRODUCING ARABINOGALACTAN COMPOUNDS DERIVED FROM PLANTS AND USES OF SAID COMPOUNDS FOR THE PROPHYLAXIS OF ALLERGIC REACTIONS
    Publication number: 20200306279
    Abstract: The present invention relates to L-arabino-oligosaccharides, in particular synthetically produced L-arabino-oligosaccharides and their uses for the prophylaxis of allergic reactions in mammals.
    Type: Application
    Filed: November 30, 2016
    Publication date: October 1, 2020
    Inventors: Marcus PETERS, Otto HOLST, Christian VOGEL, Alice VOSS
  • Enhancing medicinal properties of Hemp, Cannabis, and Cannabidiol (“CBD”) with Rhamnolipid
    Publication number: 20200306280
    Abstract: Rhamnolipid has the ability to supercharge the effectiveness of Hemp, Cannabis, and Cannabidiol (“CBD”). This is caused by rhamnolipid enhancing the effectiveness of the medicinal properties found in Hemp, Cannabis, and CBD. Rhamnolipid also has antifungal and antibacterial properties in humans when ingested and in food processing. With rhamnolipid infused with Hemp, Cannabis, and CBD, the end user can receive a supercharged medicinal effect with added antifungal and antibacterial properties.
    Type: Application
    Filed: June 6, 2019
    Publication date: October 1, 2020
    Inventor: Keith DeSanto
  • METHOD AND COMPOSITION FOR PREVENTING AND TREATING VIRAL INFECTIONS
    Publication number: 20200306281
    Abstract: A method and composition for treating viral infections using a combination of naturally occurring compounds is provided. The method includes administering to a patient at risk of or diagnosed with a viral infection a composition including therapeutically effective amounts of a helicase ATPase inhibitor, a sialidase enzyme inhibitor, an ICAM-1 inhibitor and gallic acid which each also down regulate the immune response. The composition may further include a permeation enhancer.
    Type: Application
    Filed: August 28, 2017
    Publication date: October 1, 2020
    Inventor: Daryl THOMPSON